Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PYGB | P11216 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | IGF2R | P11717 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22769085 | 1.00 | MAPK1 (0.51) | MAPK1LGALS8LGALS3LGALS4GAA | |
| SCHEMBL13480464 | 1.00 | MAPK1 (0.51) | MAPK1LGALS8LGALS3LGALS4GAA | |
| SCHEMBL13478977 | 1.00 | MAPK1 (0.51) | MAPK1LGALS8LGALS3LGALS4GAA | |
| SCHEMBL4401312 | 1.00 | MAPK1 (0.51) | MAPK1LGALS8LGALS3LGALS4GAA | |
| SCHEMBL4407553 | 1.00 | MAPK1 (0.51) | MAPK1LGALS8LGALS3LGALS4GAA | |
| SCHEMBL4411368 | 1.00 | MAPK1 (0.51) | MAPK1LGALS8LGALS3LGALS4GAA | |
| SCHEMBL13478978 | 1.00 | MAPK1 (0.51) | MAPK1LGALS8LGALS3LGALS4GAA | |
| SCHEMBL21845898 | 1.00 | MAPK1 (0.51) | MAPK1LGALS8LGALS3LGALS4GAA | |
| SCHEMBL17532204 | 0.92 | MAPK1 (0.47) | MAPK1LGALS8LGALS3LGALS4GAA | |
| SCHEMBL14210339 | 0.90 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4IGF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173843-B2 | Amphiphilic derivatives of α-C-phenyl-N-tert-butylnitrone | TS PHARMA (FR) | 2012-05-08 | — | — | US | disclosed |
| US-20090306001-A1 | NOVEL AMPHIPHILIC DERIVATIVES OF ALPHA-C-PHENYL-N-TERT-BUTYLNITRONE | TS PHARMA (FR) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306001-A1 | NOVEL AMPHIPHILIC DERIVATIVES OF ALPHA-C-PHENYL-N-TERT-BUTYLNITRONE | LIPC, TERT, POT1 | MAPK1 2949/4885LGALS8 1214/4885LGALS3 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.